Is the Butrans (buprenorphine) patch buprenorphine hydrochloride (HCl)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Butrans Patch Buprenorphine HCl?

Yes, the Butrans (buprenorphine) transdermal patch contains buprenorphine hydrochloride (HCl) as its active pharmaceutical ingredient. 1

Chemical Formulation

  • The FDA drug label explicitly states that each mL of transdermal buprenorphine solution contains 20 mg buprenorphine administered as 21.56 mg of buprenorphine hydrochloride. 1

  • The molecular formula is C29H41NO4 •HCl with a molecular weight of 504.10, confirming the hydrochloride salt formulation. 1

  • Buprenorphine HCl is a semi-synthetic opioid analgesic chemically derived from thebaine and classified as a Schedule III controlled substance. 1

Clinical Formulation Details

  • Butrans is specifically formulated as a transdermal patch delivering 5,10, or 20 mcg/hour of buprenorphine continuously over a 7-day period. 2, 3

  • The transdermal system provides sustained and consistent steady-state plasma levels, with steady state reached within 48 hours of the first patch application. 3

  • Inactive ingredients in the formulation include dehydrated alcohol, padimate O, butylated hydroxyanisole, and butylated hydroxytoluene. 1

Pharmacological Properties

  • Buprenorphine functions as a partial mu-opioid receptor agonist with high binding affinity and slow dissociation, providing prolonged analgesia. 4, 5

  • The transdermal formulation bypasses first-pass hepatic metabolism (which accounts for 90% metabolism with sublingual forms), potentially providing superior analgesia compared to oral formulations. 4, 5

  • The partial agonist properties create a ceiling effect for respiratory depression, making it safer than full opioid agonists while maintaining analgesic efficacy. 5, 6

References

Research

Transdermal buprenorphine (Butrans) for chronic pain.

The Medical letter on drugs and therapeutics, 2011

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Buprenorphine for Chronic Pain Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.